XML 23 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2021     75,752,664          
Beginning balance at Dec. 31, 2021 $ 121,463 $ (44,838) $ 8 $ 932,944 $ (53,527) $ (811,534) $ 8,689 $ 45
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock in connection with a private offering, net of offering costs (in shares)     16,649,365          
Issuance of common stock in connection with a private offering, net of offering costs $ 119,946   $ 2 119,944        
Vesting of restricted stock (in shares)     662,700          
Exercise of stock options (in shares) 270,707   270,707          
Exercise of stock options $ 1,736     1,736        
Stock-based compensation 42,553     42,553        
Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)     157,858          
Issuance of common stock pursuant to Employee Stock Purchase Plan 1,214     1,214        
Issuance of common stock for restricted stock units vested (in shares)     929,887          
Net loss (229,378)         (229,378)    
Other comprehensive (loss) income (619)             (619)
Ending balance (in shares) at Dec. 31, 2022     94,423,181          
Ending balance at Dec. 31, 2022 12,077   $ 10 1,044,864   (1,032,223)   (574)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock in connection with a private offering, net of offering costs (in shares)     129,869,440          
Issuance of common stock in connection with a private offering, net of offering costs $ 201,323   $ 13 201,310        
Vesting of restricted stock (in shares)     55,225          
Exercise of stock options (in shares) 0              
Stock-based compensation $ 28,518     28,518        
Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)     336,795          
Issuance of common stock pursuant to Employee Stock Purchase Plan 444     444        
Issuance of common stock for restricted stock units vested (in shares)     724,674          
Net loss (179,817)         (179,817)    
Other comprehensive (loss) income $ 224             224
Ending balance (in shares) at Dec. 31, 2023 225,409,315   225,409,315          
Ending balance at Dec. 31, 2023 $ 62,769   $ 23 1,275,136   (1,212,040)   (350)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of stock options (in shares) 0              
Stock-based compensation $ 20,619     20,619        
Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)     767,125          
Issuance of common stock pursuant to Employee Stock Purchase Plan 629     629        
Issuance of common stock for restricted stock units vested (in shares)     427,698          
Grant of equity option pursuant to Chiesi Collaboration Agreement 464     464        
Net loss (56,528)         (56,528)    
Other comprehensive (loss) income $ 1,539             1,539
Ending balance (in shares) at Dec. 31, 2024 226,604,138   226,604,138          
Ending balance at Dec. 31, 2024 $ 29,492   $ 23 $ 1,296,848   $ (1,268,568)   $ 1,189